Glen Santangelo analyst BARCLAYS

Currently out of the existing stock ratings of Glen Santangelo, 127 are a BUY (70.17%), 52 are a HOLD (28.73%), 2 are a SELL (1.1%).

Glen Santangelo

Work Performance Price Targets & Ratings Chart

Analyst Glen Santangelo, currently employed at BARCLAYS, carries an average stock price target met ratio of 59.39% that have a potential upside of 23.01% achieved within 213 days. Previously, Glen Santangelo worked at JEFFERIES.

Glen Santangelo’s has documented 377 price targets and ratings displayed on 43 stocks. The coverage is on Healthcare, Consumer Defensive, Technology sectors.

Most recent stock forecast was given on ALGN, Align Technology at 26-Feb-2026.

Wall Street Analyst Glen Santangelo

Analyst best performing recommendations are on TRHC (TABULA RASA HEALTHCARE).
The best stock recommendation documented was for ALGN (ALIGN TECHNOLOGY) at 10/7/2019. The price target of $200 was fulfilled within 4 days with a profit of $15.49 (8.4%) receiving and performance score of 20.99.

Average potential price target upside

ABC AmerisourceBergen BBLN Babylon Holdings Ltd CAH Cardinal Health DOCS Doximity DPLO Diplomat Pharmacy HCAT Health Catalyst HMSY HMS Holdings Corp HQY HealthEquity HSIC Henry Schein MCK McKesson MDSO Medidata Solutions PDCO Patterson Companies PGNY Progyny PHR Phreesia RAD Rite Aid TDOC Teladoc TRHC Tabula Rasa HealthCare WBA Walgreens Boots Alliance XRAY Dentsply Sirona ALGN Align Technology CVS CVS Health Corp GDRX Goodrx Holdings  RCM R1 RCM ACCD Accolade  AMWL American Well Corp ATHN athenahealth CHNG Change Healthcare HIMS Hims Hers Health DH Definitive Healthcare Corp TALK Talkspace VCRA Vocera Communications TEVA Teva Pharma Industries Ltd ADR VTRS Viatris SCPH Scpharmaceuticals AMPH Amphastar P VRCA Verrica Pharmaceuticals BHC Bausch Health Companies COLL Collegium Pharmaceutical ELAN Elanco Animal Health PCRX Pacira Pharmaceuticals SDC SmileDirectClub PHAT Phathom Pharmaceuticals NVST Envista Holdings Corp

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 10-Oct-2017

$215

$40.04 (22.89%)

$187

2 years 7 months 3 days ago
(07-Aug-2023)

14/15 (93.33%)

$28.91 (15.54%)

602

Hold Since 27-May-2022

$190

$15.04 (8.60%)

$176

2 years 7 months 7 days ago
(03-Aug-2023)

8/8 (100%)

$-0.86 (-0.45%)

433

Buy Since 05-Aug-2021

$220

$45.04 (25.74%)

$213

2 years 7 months 7 days ago
(03-Aug-2023)

11/17 (64.71%)

$29.14 (15.27%)

326

Buy Since 07-Jun-2023

$215

$40.04 (22.89%)

$200

2 years 7 months 7 days ago
(03-Aug-2023)

6/8 (75%)

$24.14 (12.65%)

220

Buy Since 08-Feb-2018

$225

$50.04 (28.60%)

$184

2 years 7 months 9 days ago
(01-Aug-2023)

11/12 (91.67%)

$36.39 (19.29%)

557

Show more analysts

Please expand the browser size to see the chart

Which stock is Glen Santangelo is most bullish on?

Potential upside of $130.74 has been obtained for MCK (MCKESSON)

Which stock is Glen Santangelo is most reserved on?

Potential downside of $0.47 has been obtained for GDRX (GOODRX HOLDINGS )

What Year was the first public recommendation made by Glen Santangelo?

On 2008

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?